BillionToOne's Northstar Response Is a Stronger Predictor of Immunotherapy Outcomes Than Standard-of-Care Imaging for Cancer Patients in Peer

Synovus Financial Corp. faces a complex outlook as its 7.7% year-over-year net interest income growth is currently overshadowed by significant credit quality concerns within its regional commercial real estate portfolio. While the bank maintains a stable divid...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q1 2026Latest Jan 21, 2026 | $1.25-11.3% vs $1.41 | — vs $615M |
Q4 2025 Oct 15, 2025 | $1.46+7.4% vs $1.36 | $615M+1.8% vs $604M |
Q3 2025 Jul 16, 2025 | $1.48+18.4% vs $1.25 | $594M+1.3% vs $586M |
Q2 2025 Apr 16, 2025 | $1.30+16.1% vs $1.12 | $569M-0.2% vs $570M |
BillionToOne's Northstar Response Is a Stronger Predictor of Immunotherapy Outcomes Than Standard-of-Care Imaging for Cancer Patients in Peer

Benchmark SNV against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Synovus Financial Corp. (SNV)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $50.05 | $6.95B | 16.52 | -7.95% | 14.09% | 9.27% | 3.03% | |
| $133.85 | $10.17B | 14.66 | 101.23% | 20.67% | 12.17% | — | |
| $143.71 | $9.69B | 12.43 | 11.23% | 20.11% | 11.93% | — | |
| $55.59 | $8.1B | 13.63 | 6.26% | 26.11% | 14.78% | — | |
| $23.02 | $10.93B | 12.24 | 10.5% | 22.31% | 11.07% | — | |
| $15.38 | $31.07B | 11.06 | 10.58% | 16.64% | 8.57% | — |
Synovus Financial Corp. (SNV) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Synovus Financial Corp. (SNV) SEC filings — annual & quarterly reports (10-K, 10-Q)
Jan 2, 2026·SEC
Dec 9, 2025·SEC
Dec 8, 2025·SEC
Feb 21, 2025·SEC
Get notified when SNV posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Synovus Financial Corp. (SNV) stock FAQ — growth, dividends, profitability & financials explained
Synovus Financial Corp. (SNV) saw revenue decline by 8.0% over the past year.
Yes, Synovus Financial Corp. (SNV) is profitable, generating $800.1M in net income for fiscal year 2024 (14.1% net margin).
Yes, Synovus Financial Corp. (SNV) pays a dividend with a yield of 3.03%. This makes it attractive for income-focused investors.
Synovus Financial Corp. (SNV) has a return on equity (ROE) of 9.3%. This is below average, suggesting room for improvement.
Synovus Financial Corp. (SNV) has a net interest margin (NIM) of 2.9%. NIM has been under pressure due to interest rate environment.
Synovus Financial Corp. (SNV) has an efficiency ratio of 36.2%. This is excellent, indicating strong cost control.